Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in First Line Treatment of Advanced EGFR Mutant NSCLC
NCT03586453Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2018
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Started Aug 2018; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03586453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586453.